Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan's Taiho Looks At Partnerships To Jumpstart Gastric Cancer Drug Global Expansion

This article was originally published in PharmAsia News

Executive Summary

Tokyo-based Taiho Pharmaceutical Nov. 19 announced the European Medicines Agency accepted for review the company's marketing application for the gastric cancer drug S-1

You may also be interested in...



Otsuka Looks To IPO To Fund Overseas Expansion

Otsuka Holdings, the parent company of Japan's fifth-largest pharmaceutical company Otsuka Pharmaceutical, could go public on the Tokyo Stock Exchange within the year

Otsuka Looks To IPO To Fund Overseas Expansion

Otsuka Holdings, the parent company of Japan's fifth-largest pharmaceutical company Otsuka Pharmaceutical, could go public on the Tokyo Stock Exchange within the year

Banyu To Sell Facility To Taiho, Move All Research To U.S.

Japan's Banyu Pharmaceutical plans to sell its research facility to Taiho Pharmaceutical, with the deal to be completed by the end of August. Banyu, a subsidiary of U.S.-based Merck, is moving its research work to the United States and assigning its employees at the Japanese facility to other divisions. The Banyu change is part of a global restructuring by Merck. For Taiho, the facility is to serve as its base for developing the cancer drugs in which it specializes. (Click here for more - a subscription may be required

UsernamePublicRestriction

Register

LL1132247

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel